Osteoarthritis is the most common chronic condition of the joints, occurring most often in the knees, hips, lower back, and neck. There are approximately 54 million patients in the U.S., of which some 760,000 patients undergo surgery costing an average $33,706, according to the U.S. Center of Disease Control and Prevention. One biotechnology company is combating this problem by utilizing autologous [the patient’s own] stem cells.
The breakthrough treatment is entering Phase II clinical trials in the United States, inching closer to commercialized regenerative medicine. The therapy collects mesenchymal stem cells [MSC] from the patient and cultures them in vitro [outside the body] to generate more stem cells After culturing the stem cells for approximately three weeks, the patients are given a weekly injection of their own stem cells. Preliminary results show cartilage restored in about six months which could preclude the need for invasive and expensive surgical procedures.
This innovative research demonstrates the integral role stem cell therapies will soon play in cutting edge medical care options. By banking their own valuable stem cells, families can ensure that they will have access to these emerging therapies in the near future. To learn more about banking stem cells, please visit StemSave or call 877-783-6728 (877-StemSave) today.
The Future of Regenerative Medicine is Now™
To view the full article, click here.